Amniotic Tissue Allograft

Phase 3Biologic

BBardia Anvar

Amniotic Tissue Allograft is one of 3 biologic programs targeting Chronic Wounds. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic WoundsNot yet recruiting

Chronic WoundsPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Chronic Wounds

#DrugCompanyPhaseTrials

Ancef

BBaxter Healthcare Corporation

Phase 2

1 2

Amniotic Tissue Allograft

BBardia Anvar

Phase 3

1 3

Dexpanthenol

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Chronic Wounds

NCT07223892

Clinical

Trials by Indication[1]

Chronic Wounds1 trial

Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds

Not yet recruiting·BBardia Anvar·Phase 3·NCT07223892·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amniotic Tissue Allograft. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amniotic Tissue Allograft compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amniotic Tissue Allograft. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bardia Anvar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBardia Anvar

Amniotic Tissue Allograft

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Chronic Wounds1 trial

References

Drug Info

Quick Facts

Related News